MOTS-c is a 16-amino-acid mitochondrial-derived peptide with a short circulating half-life: small unmodified peptides of its size are cleared from plasma within minutes to a few hours, and the endogenous exercise-induced spike in circulating MOTS-c returns toward baseline within hours. The downstream signaling it triggers - AMPK activation and a shift in metabolic gene expression - persists considerably longer than the peptide itself remains in the blood. That gap between how long the molecule circulates and how long its effects last is the single most important fact for interpreting every dosing-frequency and cycle-length question in the MOTS-c literature.
This reference is written for research and laboratory audiences. It summarizes what the published preclinical literature reports about MOTS-c pharmacokinetics, the dosing regimens investigators have actually used in animal models, and the handling and reconstitution practices common in research settings. It is not dosing guidance, and it does not describe human use. MOTS-c is offered strictly for research purposes only (RUO). No controlled interventional human pharmacokinetic trial of exogenous MOTS-c has been published, so any statement about human half-life or human dosing frequency would be speculation, and this article does not make one.
Key Findings
- MOTS-c is a small (16-amino-acid) unmodified peptide, and peptides of this class are generally cleared from circulation rapidly - on the order of minutes to a few hours - with no established human half-life for the exogenous compound.
- The biological effects run on a different clock than the peptide: AMPK signaling and the resulting transcriptional program persist well beyond plasma clearance, which is why intermittent (not continuous) dosing was sufficient in animal studies.
- Published animal regimens varied by endpoint - daily intraperitoneal injection in the original metabolic obesity studies (Lee 2015), versus a three-times-per-week intermittent schedule begun in late life in the aging study (Reynolds 2021).
- A single dose was enough to measurably improve acute exercise performance in mice (Hyatt 2022), illustrating that a short circulating window does not mean a short functional window.
- Cycle length, injection frequency, and reconstitution specifics for human research use are not established in the peer-reviewed literature; the animal data cannot be converted into a human protocol.
The Short Answer: Two Different Clocks
The most common confusion in the MOTS-c dosing conversation is treating the peptide's half-life and its duration of action as the same number. They are not.
Half-life (the time it takes for the plasma concentration of a compound to fall by half - a pharmacokinetic property describing how fast the molecule is cleared) describes how long MOTS-c stays in the blood. Duration of action (a pharmacodynamic property describing how long the biological effect persists after the compound is administered) describes how long the downstream signaling continues. For MOTS-c these two clocks are far apart: the peptide is cleared quickly, but the AMPK-driven metabolic program it switches on keeps running after the peptide is gone.
This is why researchers ask about dosing frequency at all. If the effect ended when the peptide cleared, a compound with a short half-life would need near-constant administration. The published animal data show the opposite - intermittent dosing produced sustained phenotypic effects - which only makes sense if the signal outlives the molecule.
What 'Half-Life' Means for a Peptide This Size
MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene (a ribosomal RNA region of the mitochondrial genome that also contains a non-canonical open reading frame for MOTS-c). It carries no synthetic half-life-extending modifications - no fatty-acid acylation, no PEGylation, no fusion to a carrier protein - the strategies used to make peptide drugs like the incretin agonists last for days.
Unmodified peptides in this size range are typically subject to rapid proteolysis and renal filtration, and are generally cleared from circulation on a timescale of minutes to a few hours. The published human data are indirect but consistent with this: Reynolds and colleagues documented that exercise induces a rise in circulating MOTS-c in human subjects, and such exercise-induced spikes return toward baseline over a period of hours rather than days.
What has not been published is a controlled pharmacokinetic study of exogenous (injected) MOTS-c in humans establishing an exact half-life, peak concentration, or clearance rate. Any single precise human half-life figure circulating in vendor material should be read as an estimate, not an established measurement. The honest position: short, on the order of minutes to a few hours, exact value not established in humans.
All compounds discussed are available in our catalog of research peptides for sale : 18 compounds, 99%+ purity, Aegis-verified COA.
The Pharmacokinetic-Pharmacodynamic Disconnect
The mechanistic reason the effect outlasts the molecule is that MOTS-c does not act by continuously occupying a receptor. It activates AMPK (adenosine monophosphate-activated protein kinase, the master cellular energy sensor that shifts metabolism toward glucose uptake, fat oxidation, and mitochondrial biogenesis when it is switched on) and drives a change in gene expression. Once a transcriptional program is initiated, the resulting proteins and metabolic state persist for a time governed by protein turnover and cellular adaptation, not by plasma peptide concentration.
The table below contrasts the two timescales as reported or inferred across the literature. The circulating-peptide row reflects the rapid-clearance expectation for an unmodified peptide of this size; the signaling rows reflect the downstream endpoints measured in animal studies.
| Process | Approximate timescale | Basis |
|---|---|---|
| Circulating peptide in plasma | Minutes to a few hours | Small unmodified peptide; endogenous exercise spikes return toward baseline within hours (Reynolds 2021) |
| AMPK pathway activation | Hours | Downstream kinase signaling documented in cell and animal models (Lee 2015) |
| Metabolic gene-expression program | Longer, persists past clearance | Transcriptional and phenotypic endpoints in animal studies (Lee 2015, Reynolds 2021) |
The practical consequence in the research literature: because the signal persists, investigators did not need to dose continuously to maintain an effect.
What the Dosing-Frequency Literature Actually Used
There is no established MOTS-c dosing protocol for human research use. What exists is a set of animal regimens, which differ by the question each study was asking. Reporting them is descriptive, not a recommendation.
| Study (model) | Route | Frequency | Context |
|---|---|---|---|
| Lee 2015 (diet-induced obese mice) | Intraperitoneal | Daily | Insulin sensitivity, obesity, glucose homeostasis endpoints |
| Reynolds 2021 (mice, young to old) | Intraperitoneal | Three times per week, intermittent | Physical performance and healthspan; regimen begun in late life (23.5 months) |
| Hyatt 2022 (mice) | Intraperitoneal | Single dose | Acute running performance after one administration |
Two patterns are worth noting. First, the frequency tracked the goal: daily dosing for sustained metabolic remodeling, an intermittent three-times-weekly schedule for a healthspan endpoint, a single injection for an acute-performance readout. Second, none of these are continuous-infusion designs - the short circulating half-life did not force constant administration, precisely because of the pharmacodynamic persistence described above.
Animal doses in this literature were expressed in mg/kg body weight and varied by study, spanning roughly 0.5 mg/kg per day in the original metabolic work up to about 15 mg/kg in the single-dose exercise study (Reynolds 2021 used 5 or 15 mg/kg intraperitoneally). These figures do not translate directly to any human protocol - interspecies dose conversion is not a matter of using the same number - and are provided only to characterize what the published work did.
Reconstitution and Handling in Research Settings
MOTS-c is supplied as a lyophilized (freeze-dried into a stable powder for shipping and storage) peptide. Standard laboratory reconstitution practice for a peptide of this type is to add a sterile diluent to the vial to bring the powder into solution, most commonly bacteriostatic water (sterile water containing a small percentage of benzyl alcohol as a preservative, which allows a multi-use vial to remain usable over time) or plain sterile water for single-use preparations.
General handling points reported across peptide research methods:
- Diluent is added slowly against the vial wall rather than directly onto the powder, and the vial is swirled, not shaken, to avoid shearing the peptide.
- The concentration is set by the volume of diluent added to a known mass of peptide (for example, adding 2 mL of diluent to a 10 mg vial yields 5 mg/mL); a reconstitution calculator or simple mass-per-volume arithmetic is used to work out the concentration.
- Reconstituted peptide is typically stored refrigerated and protected from light, and lyophilized powder is kept frozen for long-term storage.
Blackwell BioLabs supplies MOTS-c for research purposes only. Reconstitution here refers to laboratory sample preparation, not preparation for administration to humans. For a fuller treatment of technique, see the general reconstitution reference linked at the end of this article.
Cycle Length and Frequency Questions in the Literature
Questions about MOTS-c cycle length - how many weeks a research protocol runs, whether it is run in blocks with breaks - do not have a peer-reviewed answer for human use, and it is important to be clear about that rather than to invent one.
What the literature does provide is duration context from animal studies. The metabolic obesity work (Lee 2015) ran dosing over a period of weeks to establish changes in body weight, glucose tolerance, and insulin sensitivity. The aging study (Reynolds 2021) used an intermittent schedule sustained into late life to assess physical capacity and healthspan. These describe study durations, not cycles in the sense the term is used in applied protocol design.
The conceptual reason cycle-length questions arise for MOTS-c specifically is the same pharmacodynamic persistence discussed throughout this article: because the downstream signal outlasts the peptide, an intermittent schedule can maintain an effect without continuous exposure. Whether an optimal frequency, block length, or on-off structure exists for any human research application is unstudied. The evidence supports a general statement - the effect is durable relative to the molecule - and does not support a specific numeric protocol.
What This Research Cannot Tell You
Honesty about the boundaries of the evidence is the point of a reference like this.
- No human pharmacokinetic trial. There is no published controlled study establishing the half-life, peak concentration, clearance, or bioavailability of injected MOTS-c in humans. Human half-life numbers should be treated as estimates by analogy to peptide size, not measurements.
- No human dosing protocol. No frequency, dose, or cycle length has been validated for human research use. The animal regimens in this article characterize what studies did; they are not convertible into a human protocol, and interspecies mg/kg scaling is not linear.
- Endogenous versus exogenous. Most human MOTS-c data are observational and concern the body's own MOTS-c - levels that rise with exercise, fall with age and obesity, and vary with a mitochondrial polymorphism (the K14Q variant studied in longevity populations by Fuku 2015). These describe the natural signal, not the pharmacology of an injected dose.
- Effect duration is inferred, not directly clocked in humans. The claim that signaling outlasts the peptide rests on animal transcriptional and phenotypic endpoints plus mechanism. A direct human measurement of how long a single administered dose exerts a metabolic effect has not been published.
The defensible summary: short circulating half-life, durable downstream signaling in animal models, no established human pharmacokinetics or protocol.
View Product Specifications
Researchers studying mitochondrial-derived peptides, AMPK signaling, and metabolic pharmacology can review full specifications for MOTS-c at Blackwell BioLabs. Every lot is third-party tested with HPLC purity confirmation and mass spectrometry identity verification.
Related research references:
Published References
25738459
Lee CH, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015.
27216708
Lee C, et al. MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism. Free Radic Biol Med. 2016.
33473109
Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021.
35808870
Hyatt JK, et al. MOTS-c increases in skeletal muscle following long-term physical activity and improves acute exercise performance after a single dose. Physiol Rep. 2022.
26289118
Fuku N, et al. The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity? Aging Cell. 2015.
Research Use Only. All content is for informational and educational purposes regarding preclinical research. None of the compounds discussed have been approved by the FDA for human therapeutic use. This information does not constitute medical advice.
Frequently Asked Questions
Research by Goal
This article is part of our curated research collections. Browse all compounds in the same goal category: